Multi-omics testing for blood and bone marrow cancers
Official title: Feasibility of a Multi-omics Platform for Hematological Malignancies
Run by Azienda Ospedaliero-Universitaria di Parma · NCT07445438 · Data updated 2026-11-12
This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 1040 (estimated) |
| Sponsor | Azienda Ospedaliero-Universitaria di Parma Academic / other |
| Locations | 1 site (Parma, PR) |
| Status | Recruiting |
| Started | March 31, 2025 |
| Main results expected | March 2030 |
| Study ends | March 2030 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT07445438 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people older than 2 years with a suspected or confirmed hematologic malignancy (including newly diagnosed, relapsed/refractory, or blastic transformation) who can provide relevant diagnostic samples such as bone marrow, peripheral blood, biopsies, CSF, or other pathological fluids.
✕Probably not a fit
Patients younger than 2 years, those without available or adequate sample types, or individuals without a hematologic malignancy diagnosis are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter Italian effort combining retrospective and prospective collection of bone marrow, peripheral blood, lymph node or tissue biopsies, cerebrospinal fluid and other pathological fluids. Samples are collected during routine diagnostic or relapse work-ups at participating centers and sent fresh or frozen to a central laboratory at the University of Parma for analysis. The laboratory will perform integrated multi-omics assays and functional tests to profile genetic, molecular, and cellular features across the full range of WHO 2022 hematologic entities. The goal is to test the feasibility of applying this platform across different sample types and clinical settings.
Why it matters
Potential benefit: If successful, this approach could give more detailed molecular and functional information to help refine diagnoses and guide personalized treatment choices.
How similar studies have gone: Multi-omics approaches have shown promise in research settings for identifying actionable mutations and disease subtypes, but multicenter feasibility and routine clinical integration are still being established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged \> 2 year old * Retrospective study: * Patients previously diagnosed with hematological malignancies * Prospective study: * Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion). * Patients with clinical suspicion of R/R onco-hematological disorder, requiring a diagnostic assessment using BM aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc. * Patients with blastic transformation from a chronic condition or suspect of R/R hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate/biopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc. Exclusion Criteria: * Age \<2 year old * Patient without a diagnosis of hematological malignancy.
Where it's running
-
University of Parma
Parma, Pr, Italy Recruiting
Study contacts
- Study coordinator: Giovanni Roti, Associate Professor
- Email: giovanni.roti@unipr.it
- Phone: +39 0521 702200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chemogenomic profiling for blood cancers
This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.
-
Comprehensive multi-omics and functional profiling to fully characterize tumors
This project tests whether detailed multi-omics and functional testing of tumor samples can better characterize high-risk blood and solid cancers for patients at participating centers.
-
KLN-1010 gene therapy for relapsed or refractory multiple myeloma
This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.
-
Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant
This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.
-
Preventing Acute GVHD After Stem Cell Transplant
This study is testing a new way to give a medication before and during stem cell transplants to see if it can help prevent a serious condition called acute GVHD in patients.
-
Transplanting umbilical cord blood from unrelated donors
This study is testing different ways to prepare patients for umbilical cord blood stem cell transplants to see how safe and effective the procedure is for them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.